Akoya BioSciencesAKYA
AKYA
About: Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Its PhenoCycler (formerly CODEX) and PhenoImager (formerly Phenoptics) platforms, reagents, software, and services, It offer end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.
Employees: 330
0
Funds holding %
of 7,139 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
2,380% more call options, than puts
Call options by funds: $124K | Put options by funds: $5K
46% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 13
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
2% more funds holding
Funds holding: 59 [Q3] → 60 (+1) [Q4]
0.03% more ownership
Funds ownership: 24.45% [Q3] → 24.49% (+0.03%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
16% less capital invested
Capital invested by funds: $32.9M [Q3] → $27.8M (-$5.13M) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for AKYA.
Financial journalist opinion
Based on 3 articles about AKYA published over the past 30 days
Neutral
Business Wire
3 days ago
Kent Lake Issues Letter to Quanterix Shareholders Regarding Opposition to the Company's Proposed Merger with Akoya Biosciences
RINCON, Puerto Rico--(BUSINESS WIRE)--Kent Lake PR LLC (“Kent Lake”), a holder of 5.9% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), today highlighted its opposition to the Company's proposed merger (the “Merger”) with Akoya Biosciences (“Akoya”) (NASDAQ: AKYA). Kent Lake has also issued an open letter to all Quanterix shareholders outlining how the Merger significantly undervalues the Company and its intention to take all necessary step.
Neutral
GlobeNewsWire
2 weeks ago
Akoya Biosciences Unveils Strategic Product Roadmap, Powered by the New IO60 and Upcoming Neurobiology Panels
Rapid menu expansion with new high-plex human and mouse neurobiology panels joining the recently launched Human IO60 and Mouse FFPE IO Panels
Neutral
Business Wire
3 weeks ago
Akoya Biosciences Selects Argonaut Manufacturing Services as IVD Manufacturing Partner
CARLSBAD, Calif.--(BUSINESS WIRE)--Argonaut Manufacturing Services (“Argonaut”), a leading contract development and manufacturing organization serving the biopharma and life sciences industries, and Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, announced today that Argonaut will act as the manufacturing partner for Akoya's IVD assays currently in development. This agreement builds on years of collaboration between Argonaut and Akoya, reflecting Argonaut's prove.
Neutral
Business Wire
1 month ago
AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Akoya Biosciences, Inc. (NasdaqGS: AKYA) to Quanterix Corporation (NasdaqGM: QTRX). Under the terms of the proposed transaction, shareholders of Akoya will receive 0.318 shares of Quanterix for each share of Akoya that they own. KSF is seeking to determine whether this consideration and the process that led to.
Neutral
Business Wire
1 month ago
Shareholder Alert: Ademi LLP Investigates Whether Akoya Biosciences, Inc. Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Akoya (NASDAQ: AKYA) for possible breaches of fiduciary duty and other violations of law in its transaction with Quanterix. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Akoya stockholders will receive only 0.318 shares of Quanterix common stock for each share of Akoya common stock.
Neutral
Business Wire
1 month ago
AKYA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akoya Biosciences, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Akoya Biosciences, Inc. (NASDAQ: AKYA) to Quanterix Corporation for 0.318 shares of Quanterix common stock for each share of Akoya common stock is fair to Akoya shareholders. Halper Sadeh encourages Akoya shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersad.
Neutral
Business Wire
1 month ago
Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers
BILLERICA, Mass. and MARLBOROUGH, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (NASDAQ: AKYA), The Spatial Biology Company®, today announced a definitive merger agreement under which Quanterix will acquire Akoya in an all-stock transaction. The transaction will create the first integrated solution for ultra-sensitive detection of blood- and tissue-based protein biomarkers.
Neutral
GlobeNewsWire
2 months ago
Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions
Akoya expands clinical test menu, exclusively licensing the global rights to develop and commercialize NeraCare's Immunoprint test for prognostication of disease recurrence in early-stage melanoma patients to better guide treatment decisions and potentially increase access to life saving therapies for those patients at high risk of developing metastatic disease Akoya expands clinical test menu, exclusively licensing the global rights to develop and commercialize NeraCare's Immunoprint test for prognostication of disease recurrence in early-stage melanoma patients to better guide treatment decisions and potentially increase access to life saving therapies for those patients at high risk of developing metastatic disease
Neutral
Seeking Alpha
3 months ago
Akoya Biosciences, Inc. (AKYA) Q3 2024 Earnings Call Transcript
Akoya Biosciences, Inc. (NASDAQ:AKYA ) Q3 2024 Earnings Conference Call November 14, 2024 5:00 PM ET Company Participants Priyam Shah - Head, IR Brian McKelligon - CEO Johnny Ek - CFO Conference Call Participants William Bonello - Craig-Hallum Mason Carrico - Stephens Kyle Mikson - Canaccord David Westenberg - Piper Tejas Savant - Morgan Stanley Subbu Nambi - Guggenheim Securities Mark Massaro - BTIG Operator Hello and thank you for standing by. Welcome to the Akoya Biosciences Third Quarter 2024 Earnings Conference Call.
Negative
Zacks Investment Research
3 months ago
Akoya Biosciences (AKYA) Reports Q3 Loss, Lags Revenue Estimates
Akoya Biosciences (AKYA) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.26 per share a year ago.
Charts implemented using Lightweight Charts™